Eikon Therapeutics, Inc.

EIKN

Figures shown here come from public SEC filings. Dates beside each section show the available history.

Annual Financial Review

Annual financial history is not available for this company.

SEC filings supply these figures; updates after the dates shown are not included. No annual financial history is available for this company. The latest insider filing shown is dated Mar 4, 2026.

Ownership

Who holds the shares, as reported in SEC ownership filings.

Independent insiders buying near the same time

2026-02-04–2026-02-06: 6 event(s) across 4 owner(s) — A cluster counts independent reporting owners that reported purchases within a set time. Co-filers and declared affiliates count once, and duplicate reports of the same event count once. ( filing , filing , filing , filing , filing , filing )

Purchases & sales (open market or private)

		Security	Code		Price	Filing
2026-02-06	Svennilson Peter · 10% owner	Common Stock	P — Open market or private purchase	+1,437,323	18.00	SEC filing
2026-02-06	Svennilson Peter · 10% owner	Common Stock	P — Open market or private purchase	+49,556	18.00	SEC filing
2026-02-06	Svennilson Peter · 10% owner	Common Stock	P — Open market or private purchase	+630,881	18.00	SEC filing
2026-02-04	Foresite Capital Fund IV, L.P. · 10% owner	Common Stock	P — Open market or private purchase	+55,555	18.00	SEC filing
2026-02-04	FRAZIER KENNETH C · Director	Common Stock	P — Open market or private purchase	+111,111	18.00	SEC filing
2026-02-04	Wolfe Josh · Director, 10% owner	Common Stock	P — Open market or private purchase	+138,888	18.00	SEC filing

Showing 6 of 6 rows

Grants, exercises, tax & gifts

		Security	Code		Filing
2026-03-02	Thorner Benjamin Bruno · See Remarks	Stock Option (Right to Buy)	A — Grant, award, or other acquisition	+67,044	SEC filing
2026-03-02	Bowie Alfred Lloyd Jr. · Chief Financial Officer	Stock Option (Right to Buy)	A — Grant, award, or other acquisition	+67,044	SEC filing
2026-03-02	Baynes Roy D. · Chief Medical Officer	Stock Option (Right to Buy)	A — Grant, award, or other acquisition	+134,088	SEC filing
2026-03-02	PERLMUTTER ROGER M · See remarks	Stock Option (Right to Buy)	A — Grant, award, or other acquisition	+268,176	SEC filing
2026-03-02	Huffines Robert Luther · Director	Stock Option (Right to Buy)	A — Grant, award, or other acquisition	+25,873	SEC filing
2026-03-02	FRAZIER KENNETH C · Director	Stock Option (Right to Buy)	A — Grant, award, or other acquisition	+25,873	SEC filing
2026-03-02	Klobuchar Michael A · Chief Operating Officer	Stock Option (Right to Buy)	A — Grant, award, or other acquisition	+87,157	SEC filing
2026-02-06	Svennilson Peter · 10% owner	Common Stock	C — Conversion of derivative security	+110,928	SEC filing

Showing 8 of 17 rows

These tables describe filed transactions, not current holdings. Prices are shown as filed; a currency is added only when the filing's data names one. Amended and possible duplicate rows are left out of size comparisons and transaction groups.